Drug safety: managing innovation in rheumatology
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia, Pa.
Elsevier
2012
|
| Schriftenreihe: | Rheumatic disease clinics of North America
38,4 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIV S., S. 654 - 818 Ill., graph. Darst. |
| ISBN: | 9781455750658 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV040660528 | ||
| 003 | DE-604 | ||
| 005 | 20130114 | ||
| 007 | t | ||
| 008 | 130109s2012 ad|| |||| 00||| eng d | ||
| 020 | |a 9781455750658 |9 978-1-4557-5065-8 | ||
| 035 | |a (OCoLC)826576176 | ||
| 035 | |a (DE-599)BVBBV040660528 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 084 | |a XI 5100 |0 (DE-625)153011:12905 |2 rvk | ||
| 084 | |a YC 8700 |0 (DE-625)153265: |2 rvk | ||
| 245 | 1 | 0 | |a Drug safety |b managing innovation in rheumatology |c ed.: John J. Cush ... |
| 264 | 1 | |a Philadelphia, Pa. |b Elsevier |c 2012 | |
| 300 | |a XIV S., S. 654 - 818 |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Rheumatic disease clinics of North America |v 38,4 | |
| 490 | 0 | |a Clinics review articles | |
| 650 | 0 | 7 | |a Antirheumatikum |0 (DE-588)4002332-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelsicherheit |0 (DE-588)4143182-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Antirheumatikum |0 (DE-588)4002332-1 |D s |
| 689 | 0 | 1 | |a Arzneimittelsicherheit |0 (DE-588)4143182-0 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Cush, John J. |e Sonstige |4 oth | |
| 830 | 0 | |a Rheumatic disease clinics of North America |v 38,4 |w (DE-604)BV000625464 |9 38,4 | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025487295&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-025487295 | ||
Datensatz im Suchindex
| _version_ | 1804149783527424000 |
|---|---|
| adam_text | Drug Safety: Managing Innovation in Rheumatology
Contents
Foreword jx
Michael H. Weisman
Preface: Refining Drug Safety in Rheumatology
xi
John J. Cush and Kathryn H.
Dao
Communicating the Risk of Side Effects to Rheumatic Patients
653
Richard W. Martin
When proposing a new therapy, rheumatologists must inform patients of
a range of therapeutic options and support them towards making an
informed decision. This article introduces definitions of equipoise and
a good decision, contrasts persuasion from informed patient choice, and
discussed the effects of patient characteristics including cognition on
decision making. It also describes and offers examples of techniques
and visual formats utilized in patient decision aids to present risk estimates
to reduce cognitive bias and maximize patient comprehension.
Safety of Urate-Lowering Therapies: Managing the Risks to Gain the Benefits
663
Robert T. Keenan
Gout is a metabolic disorder of
purine
metabolism and
une
acid elimina¬
tion. Over time, acute gout can develop into a chronic, disabling arthrop-
athy, often associated with multiple comorbidities. Gout patients have
often been undertreated, partly because of the clinician s perceived risks
of a therapy outweighing its potential benefits. The approval of new thera¬
pies to treat hypenjiicemia in gout has led to a new understanding of gout
management and medication safety regarding new and old therapies. This
review focuses on potential safety issues of currently available urate-low-
ering therapies and outlines strategies to minimize risks so their benefits
can be reached.
Safety of Bisphosphonates
681
Catalina
Orozco and Nairn M. Maalouf
Bisphosphonates are antiresorptive medications widely prescribed for
treating osteoporosis. In placebo-controlled clinical trials they have been
shown to significantly reduce the risk of osteoporotic fractures. However,
reports of atypical femoral fractures and osteonecrosis of the jaw have
emerged with long-term use, raising questions regarding their long-term
safety. Additionally, questions have also emerged regarding the associa¬
tion between bisphosphonates and other rare adverse events, such as
esophageal cancer and atrial fibrillation. This article summarizes the
current knowledge regarding
tne
major side effects associated with the
use of bisphosphonates, identifies at-risk populations for these side
effects, and provides guidance for their use.
Contents
Nonserious Infections:
Should There Be Cause for Serious Concerns?
707
Kathryn H.
Dao,
Morley Herbert,
Nadia
Habal, and John J. Cush
Nonserious infections (NSIE) as colds, flu syndromes, and urinary tract
infection, are the most common infections seen in patients with immune
mediated inflammatory diseases. Yet, little is known about the impact of
immunosuppresslon, particularly with tumor necrosis factor inhibitors
(TNR), on these infections. A systemic review of large, randomized con¬
trolled trials was conducted to identify incidence, types, and outcomes of
NSIE associated with the most commonly prescribed TNFi: adalimumab,
etanercept, and infliximab.
Infections and Biologic Therapy in Rheumatoid Arthritis: Our Changing
Understanding of Risk and Prevention
727
Kevin L. Winthrop
Patients with rheumatoid arthritis are at higher risk for serious infections and
death from infection than the general public. Prednisone and biologic
agents increase this risk, although the risk associated with biologies can
be mitigated when such agents act as prednisone-sparing therapies.
Some of the important causes of infectious morbidity in this setting are pre¬
ventable with screening (eg, tuberculosis) or vaccination (eg, herpes zoster).
Perioperative
Drug Safety in Patients with Rheumatoid Arthritis
747
Susan M. Goodman and Stephen Paget
The expansion of therapeutic options for rheumatoid arthritis (RA) has
improved the functional, quality of life, and
radiographie
outcomes for
patients, although immunomodulatory and immunosuppressive effects
may increase the potential for complications related to infection risk or wound
healing after orthopedic surgery. Additionally, medications without signifi¬
cant effects on the immune system, such as nonsteroidal anti-inflammatory
drugs, may have consequences in terms of bleeding or cardiovascular dis¬
ease. Increased vigilance is required when using these medications, partic¬
ularly in the
perioperative
period. This article considers the recent literature
and data on the
perioperative
use of medications commonly used in RA.
Malignancy Risks With Biologic Therapies
761
John J. Cush and Kathryn H.
Dao
The management of rheumatoid arthritis (RA) dramatically changed in
1998
with the introduction of etanercept and infliximab for the treatment of RA
and Crohn colitis. Nine biologic agents are currently in use for treating
RA. However, speculation has grown that the long-term use of these bio-
pharmaceuticals may alter normal ¡mmunosurveillance, thereby contribut¬
ing to an individual s cancer risk. Whether malignancy is a consequence of
rheumatoid inflammation or the therapies used to treat RA has been unclear
until recently. This article addresses the growing data on the short- and
long-term cancer risks associated with biologic use in RA.
Safe Use of Antirheumatic Agents in Patients with Comorbidities
771
Ashima Makol, Kerry Wright, and Eric L.
Matteson
The burden of comorbid diseases is high among patients with rheumatoid
arthritis (RA). These are often systemic manifestations of RA but may be
Contents
chronic conditions that predate or develop post-RA diagnosis. Increased
mortality in RA is predominantly from nonarticular causes. The expanded
armamentarium of disease-modifying drugs and biologies available has
revolutionized management of articular disease but has made safe treat¬
ment of RA more complex. Drug-induced organ injury and side effects
need to be kept in mind when initiating or modifying therapy.
Comparative Safety of Therapies in Systemic Lupus Erythematosus
795
Joseph Mosak and Richard
Furie
Systemic lupus erythematosus (SLE) is the
prototypie
autoimmune disease
with diverse clinical manifestations, affecting virtually all organ systems.
A wide variety of medications are used for treatment, depending on organ
involvement and severity. This article summarizes the adverse effects
associated with different drugs currently used to treat SLE.
Index
809
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV040660528 |
| classification_rvk | XI 5100 YC 8700 |
| ctrlnum | (OCoLC)826576176 (DE-599)BVBBV040660528 |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01640nam a2200397 cb4500</leader><controlfield tag="001">BV040660528</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20130114 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">130109s2012 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781455750658</subfield><subfield code="9">978-1-4557-5065-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)826576176</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV040660528</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 5100</subfield><subfield code="0">(DE-625)153011:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YC 8700</subfield><subfield code="0">(DE-625)153265:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug safety</subfield><subfield code="b">managing innovation in rheumatology</subfield><subfield code="c">ed.: John J. Cush ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia, Pa.</subfield><subfield code="b">Elsevier</subfield><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIV S., S. 654 - 818</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Rheumatic disease clinics of North America</subfield><subfield code="v">38,4</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Clinics review articles</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antirheumatikum</subfield><subfield code="0">(DE-588)4002332-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelsicherheit</subfield><subfield code="0">(DE-588)4143182-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Antirheumatikum</subfield><subfield code="0">(DE-588)4002332-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelsicherheit</subfield><subfield code="0">(DE-588)4143182-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cush, John J.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Rheumatic disease clinics of North America</subfield><subfield code="v">38,4</subfield><subfield code="w">(DE-604)BV000625464</subfield><subfield code="9">38,4</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025487295&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-025487295</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV040660528 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T00:28:31Z |
| institution | BVB |
| isbn | 9781455750658 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-025487295 |
| oclc_num | 826576176 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | XIV S., S. 654 - 818 Ill., graph. Darst. |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | Elsevier |
| record_format | marc |
| series | Rheumatic disease clinics of North America |
| series2 | Rheumatic disease clinics of North America Clinics review articles |
| spelling | Drug safety managing innovation in rheumatology ed.: John J. Cush ... Philadelphia, Pa. Elsevier 2012 XIV S., S. 654 - 818 Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Rheumatic disease clinics of North America 38,4 Clinics review articles Antirheumatikum (DE-588)4002332-1 gnd rswk-swf Arzneimittelsicherheit (DE-588)4143182-0 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Antirheumatikum (DE-588)4002332-1 s Arzneimittelsicherheit (DE-588)4143182-0 s DE-604 Cush, John J. Sonstige oth Rheumatic disease clinics of North America 38,4 (DE-604)BV000625464 38,4 Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025487295&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Drug safety managing innovation in rheumatology Rheumatic disease clinics of North America Antirheumatikum (DE-588)4002332-1 gnd Arzneimittelsicherheit (DE-588)4143182-0 gnd |
| subject_GND | (DE-588)4002332-1 (DE-588)4143182-0 (DE-588)4143413-4 |
| title | Drug safety managing innovation in rheumatology |
| title_auth | Drug safety managing innovation in rheumatology |
| title_exact_search | Drug safety managing innovation in rheumatology |
| title_full | Drug safety managing innovation in rheumatology ed.: John J. Cush ... |
| title_fullStr | Drug safety managing innovation in rheumatology ed.: John J. Cush ... |
| title_full_unstemmed | Drug safety managing innovation in rheumatology ed.: John J. Cush ... |
| title_short | Drug safety |
| title_sort | drug safety managing innovation in rheumatology |
| title_sub | managing innovation in rheumatology |
| topic | Antirheumatikum (DE-588)4002332-1 gnd Arzneimittelsicherheit (DE-588)4143182-0 gnd |
| topic_facet | Antirheumatikum Arzneimittelsicherheit Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025487295&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000625464 |
| work_keys_str_mv | AT cushjohnj drugsafetymanaginginnovationinrheumatology |